MoonLake Immunotherapeutics announced Week 52 results from its Phase 3 VELA trials showing sonelokimab significantly improves symptoms in adults with moderate-to-severe hidradenitis suppurativa (HS), with 67% achieving HiSCR75 and 26% reaching inflammatory remission. The treatment also improved quality of life and reduced pain, with no new safety concerns. Positive interim results in adolescents were reported, and a Biologics License Application is planned for submission to the FDA by September 2026. An Investor Day webcast is scheduled for June 22, 2026, to discuss these results and upcoming milestones.
Bitcoin traders are debating whether to buy in the $40,000 to $50,000 range as a potential entry point, with analyst Michaël van de Poppe warning that widely expected price targets often fail to materialize. Meanwhile, Michael Saylor's company Strate...
Gold prices declined for the third consecutive week, dropping to around $4,156 due to a stronger U.S. dollar and expectations of Federal Reserve rate hikes. Despite a midweek rally sparked by easing U.S.-Iran tensions, the Fed's hawkish signals and r...
A preliminary peace framework between the U.S. and Iran has driven crude oil prices to their lowest in over three months, falling below $80 per barrel, and gasoline prices have dropped about 30% in two months. This deal, still under negotiation with ...
The Health Care Select Sector SPDR ETF (XLV) is down about 3% year-to-date despite a 14% gain over the past year. The fund's performance hinges on drug pricing policies and key product pricing, especially from Eli Lilly, which dominates XLV with its ...
XRP is trading near $1.14, balancing ETF inflows and reduced exchange reserves against whale selling and short-term price weakness. Despite a 16% drop over 30 days, institutional demand through XRP ETFs remains strong, with net inflows exceeding $10 ...
